Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases. Their work, published this month in Neurology, may suggest a neuroprotective target for drug discovery efforts.
"This is the first epigenetic modification of a gene that seems to be protective against neuronal disease," says lead author Corey McMillan, PhD, research assistant professor of Neurology in the Frontotemporal Degeneration Center in the Perelman School of Medicine at the University of Pennsylvania.
Expansions in the offending gene, C9orf72, have been linked with TAR DNA binding protein (TDP-43) which is the pathological source that causes ALS and FTD. "Understanding the role of C9orf72 has the possibility to be truly translational and improve the lives of patients suffering from these devastating diseases," says senior author, Edward Lee, MD, PhD, assistant professor of Neuropathology in Pathology and Laboratory Medicine at Penn.
McMillan and team evaluated 20 patients recruited from both the FTD Center and the ALS Center at the University of Pennsylvania who screened positive for a mutation in the C9orf72 gene and were clinically diagnosed with FTD or ALS. All patients completed a neuroimaging study, a blood test to evaluate C9orf72 methylation levels, and a brief neuropsychological screening assessment. The study also included 25 heathy controls with no history of neurological or psychiatric disease.
MRI revealed reduced grey matter in several regions that were affected in patients compared to controls. Grey matter is needed for the proper function of the brain in regions involved with muscle control, memory, emotions, speech and decision-making. Critically, patients with hypermethylation of C9orf72 showed more dense grey matter in the hippocampus, frontal cortex, and thalamus, regions of the brain important for the above described tasks and affected in ALS and FTD, suggesting that hypermethylation is neuroprotective in these regions.
To validate these findings, the Penn team also looked at autopsies of 35 patients with C9orf72 expansions and found that their pathology also suggested that increased methylation was associated with reduced neuronal loss in both the frontal cortex and hippocampus.
Longitudinal analysis was performed in 11 of the study patients to evaluate the neuroprotective effects of hypermethylation in individuals over their disease course. This showed reduced changes in grey matter of the hippocampus, thalamus, and frontal cortex, associated with hypermethlation suggesting that disease progresses more slowly over time in individuals with C9orf72 hypermethylation. Longitudinal neuropsychological assessments also showed a correlation between protected memory decline and hypermethylation.
These findings are consistent with a growing number of studies which have suggested the neuroprotective effects of the hypermethylation of C9orf72. "We believe that this work provides additional data supporting the notion that C9orf72 methylation is neuroprotective and therefore opens up the exciting possibility of a new avenue for precision medicine treatments and targets for drug development in neurodegenerative disease," says McMillan.
Explore further: Researchers develop strategy to combat genetic ALS, FTD
Medical Xpress on facebook
Related Stories
Staging system in ALS shows potential tracks of disease progression, study finds
Jun 19, 2013
The motor neuron disease Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, progresses in a stepwise, sequential pattern which can be classified into four distinct stages, report pathologists with the ...
Identification of abnormal protein may help diagnose, treat ALS and frontotemporal dementia
Feb 12, 2013
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and frontotemporal dementia (FTD) are devastating neurodegenerative diseases with no effective treatment. Researchers are beginning to recognize ...
Researchers develop strategy to combat genetic ALS, FTD
Aug 14, 2014
A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral ...
'RNA sponge' mechanism may cause ALS/FTD neurodegeneration
Apr 01, 2013
The most common genetic cause of both ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) was recently identified as an alteration in the gene C9orf72. But how the mutation causes neurodegenerative disease ...
Team gains new insight into how motor neurons in the brain die during ALS
Dec 17, 2014
Researchers look to understand the causes of amyotrophic lateral sclerosis (ALS), in the hope of finding new ways to treat the disease. A new study published online today in the Cell Press journal Neuron shows ...
Recommended for you
Power naps produce a significant improvement in memory performance
8 hours ago
A team of researchers at Saarland University headed by Professor Axel Mecklinger have shown that a short nap lasting about an hour can significantly improve memory performance. The study, which was coordinated ...
Having a purpose in life may improve health of aging brain
12 hours ago
Having a strong sense that your life has meaning and direction may make you less likely to develop areas of brain damage caused by blockages in blood flow as you age. This research is reported in the American ...
America's aging population will require more neurosurgeons for increased brain bleeds
16 hours ago
By 2030, chronic subdural hemorrhage (SDH) will be the most common adult brain condition requiring neurosurgical intervention in the U.S., according to a new study conducted by researchers at NYU Langone Medical Center. And ...
New assessment tool helps predict risk of cognitive decline
Mar 19, 2015
(HealthDay)—A new assessment tool may be able to predict risk of mild cognitive impairment (MCI) in older adults, according to a study published online March 18 in Neurology.
Altering brain chemistry makes us more sensitive to inequality
Mar 19, 2015
What if there were a pill that made you more compassionate and more likely to give spare change to someone less fortunate? UC Berkeley scientists have taken a big step in that direction.
Our eyes multi-task even when we don't want them to, researchers find
Mar 19, 2015
Our eyes are drawn to several dimensions of an object—such as color, texture, and luminance—even when we need to focus on only one of them, researchers at New York University and the University of Pennsylvania ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases. Their work, published this month in Neurology, may suggest a neuroprotective target for drug discovery efforts.
"This is the first epigenetic modification of a gene that seems to be protective against neuronal disease," says lead author Corey McMillan, PhD, research assistant professor of Neurology in the Frontotemporal Degeneration Center in the Perelman School of Medicine at the University of Pennsylvania.
Expansions in the offending gene, C9orf72, have been linked with TAR DNA binding protein (TDP-43) which is the pathological source that causes ALS and FTD. "Understanding the role of C9orf72 has the possibility to be truly translational and improve the lives of patients suffering from these devastating diseases," says senior author, Edward Lee, MD, PhD, assistant professor of Neuropathology in Pathology and Laboratory Medicine at Penn.
McMillan and team evaluated 20 patients recruited from both the FTD Center and the ALS Center at the University of Pennsylvania who screened positive for a mutation in the C9orf72 gene and were clinically diagnosed with FTD or ALS. All patients completed a neuroimaging study, a blood test to evaluate C9orf72 methylation levels, and a brief neuropsychological screening assessment. The study also included 25 heathy controls with no history of neurological or psychiatric disease.
MRI revealed reduced grey matter in several regions that were affected in patients compared to controls. Grey matter is needed for the proper function of the brain in regions involved with muscle control, memory, emotions, speech and decision-making. Critically, patients with hypermethylation of C9orf72 showed more dense grey matter in the hippocampus, frontal cortex, and thalamus, regions of the brain important for the above described tasks and affected in ALS and FTD, suggesting that hypermethylation is neuroprotective in these regions.
To validate these findings, the Penn team also looked at autopsies of 35 patients with C9orf72 expansions and found that their pathology also suggested that increased methylation was associated with reduced neuronal loss in both the frontal cortex and hippocampus.
Longitudinal analysis was performed in 11 of the study patients to evaluate the neuroprotective effects of hypermethylation in individuals over their disease course. This showed reduced changes in grey matter of the hippocampus, thalamus, and frontal cortex, associated with hypermethlation suggesting that disease progresses more slowly over time in individuals with C9orf72 hypermethylation. Longitudinal neuropsychological assessments also showed a correlation between protected memory decline and hypermethylation.
These findings are consistent with a growing number of studies which have suggested the neuroprotective effects of the hypermethylation of C9orf72. "We believe that this work provides additional data supporting the notion that C9orf72 methylation is neuroprotective and therefore opens up the exciting possibility of a new avenue for precision medicine treatments and targets for drug development in neurodegenerative disease," says McMillan.
Explore further: Researchers develop strategy to combat genetic ALS, FTD
Medical Xpress on facebook
Related Stories
Staging system in ALS shows potential tracks of disease progression, study finds
Jun 19, 2013
The motor neuron disease Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, progresses in a stepwise, sequential pattern which can be classified into four distinct stages, report pathologists with the ...
Identification of abnormal protein may help diagnose, treat ALS and frontotemporal dementia
Feb 12, 2013
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and frontotemporal dementia (FTD) are devastating neurodegenerative diseases with no effective treatment. Researchers are beginning to recognize ...
Researchers develop strategy to combat genetic ALS, FTD
Aug 14, 2014
A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral ...
'RNA sponge' mechanism may cause ALS/FTD neurodegeneration
Apr 01, 2013
The most common genetic cause of both ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) was recently identified as an alteration in the gene C9orf72. But how the mutation causes neurodegenerative disease ...
Team gains new insight into how motor neurons in the brain die during ALS
Dec 17, 2014
Researchers look to understand the causes of amyotrophic lateral sclerosis (ALS), in the hope of finding new ways to treat the disease. A new study published online today in the Cell Press journal Neuron shows ...
Recommended for you
Power naps produce a significant improvement in memory performance
8 hours ago
A team of researchers at Saarland University headed by Professor Axel Mecklinger have shown that a short nap lasting about an hour can significantly improve memory performance. The study, which was coordinated ...
Having a purpose in life may improve health of aging brain
12 hours ago
Having a strong sense that your life has meaning and direction may make you less likely to develop areas of brain damage caused by blockages in blood flow as you age. This research is reported in the American ...
America's aging population will require more neurosurgeons for increased brain bleeds
16 hours ago
By 2030, chronic subdural hemorrhage (SDH) will be the most common adult brain condition requiring neurosurgical intervention in the U.S., according to a new study conducted by researchers at NYU Langone Medical Center. And ...
New assessment tool helps predict risk of cognitive decline
Mar 19, 2015
(HealthDay)—A new assessment tool may be able to predict risk of mild cognitive impairment (MCI) in older adults, according to a study published online March 18 in Neurology.
Altering brain chemistry makes us more sensitive to inequality
Mar 19, 2015
What if there were a pill that made you more compassionate and more likely to give spare change to someone less fortunate? UC Berkeley scientists have taken a big step in that direction.
Our eyes multi-task even when we don't want them to, researchers find
Mar 19, 2015
Our eyes are drawn to several dimensions of an object—such as color, texture, and luminance—even when we need to focus on only one of them, researchers at New York University and the University of Pennsylvania ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment